Latest Regulatory News

Hot Chili Limited confirms a significant copper-gold mineralisation footprint at its La Verde discovery in Chile, completing phase-one drilling and advancing strategic funding discussions for its key projects.

Nova Eye Medical has reported a record A$29.2 million revenue for FY25, driven by strong sales growth and improved profitability in its glaucoma segment. The company targets breakeven EBITDA in the first half of FY26 alongside continued cash flow improvements.

Chimeric Therapeutics has advanced its CHM CDH17 CAR-T program with dose escalation and FDA Fast Track status, alongside promising early results in AML trials and a successful $6.6 million capital raise.

Aurora Energy Metals has secured a six-month extension on Eagle Energy Metals' exclusive option for its flagship uranium project, accompanied by significant cash inflows and advancing metallurgical work. The company ends the quarter debt-free with a solid cash buffer as it pushes forward on multiple fronts.

Epsilon Healthcare has completed a $6.7 million sale and leaseback of its Southport manufacturing site, significantly reducing debt and securing long-term operational stability.

GTN Limited shareholders have overwhelmingly approved a capital return, setting the stage for a payment scheduled on 11 August 2025. This move reflects the company’s ongoing strategy to optimise shareholder value.

Accent Resources has initiated a Pre-Feasibility Study for its Magnetite Range Iron Ore Project, while maintaining steady gold resources at Norseman and reporting a strong cash position of $13 million.

Manuka Resources has declared a maiden Probable Ore Reserve of 39,000 ounces of gold at its historic Mt Boppy Open Pit, underpinning a cutback project that adds significant value to its Cobar Basin production plan.

Aurum Resources has reported impressive high-grade gold assay results from its extensive diamond drilling at the Boundiali Gold Project in Côte d'Ivoire, reinforcing the project's potential and underpinning ambitious exploration and development targets for 2025.

Radiopharm Theranostics reports significant progress in its oncology radiopharmaceutical pipeline, including FDA Fast Track designation and dose escalation approvals, supported by a solid cash runway through mid-2026.

Prescient Therapeutics has raised $6.8 million through a Share Purchase Plan to fund the Phase 2 development of its novel cancer therapy PTX-100, while launching a discounted placement to sophisticated investors.

Atomo Diagnostics reports strong commercial momentum in Q4 FY25, highlighted by a major US supply agreement, rapid growth in HIV self-test sales, and promising data for its syphilis test.